Azitra (AZTR) Common Equity (2022 - 2026)
Azitra (AZTR) posted Common Equity of $10.5 million for Q1 2026, up 175.71% on a QoQ basis from $3.8 million in Q4 2025, and up 137.7% year-over-year from $4.4 million in Q1 2025.
Azitra (AZTR) Common Equity (2022 - 2026) Analysis & Trends
Azitra's Common Equity history runs 5 years deep, the most recent figure standing at $10.5 million for Q1 2026.
- Quarterly Common Equity rose 137.7% year-over-year to $10.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 million (up 137.7% YoY) and the FY2025 annual result came in at $3.8 million, down 33.29% from the prior year.
- Common Equity was $10.5 million for Q1 2026 at Azitra, up from $3.8 million in the prior quarter.
- Across five years, Common Equity topped out at $10.5 million in Q1 2026 and bottomed at -$38.7 million in Q1 2023.
- A 5-year average of -$4.9 million and a median of $3.4 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity tumbled 76.15% — and 2026, when it soared 137.7%.
- Azitra's Common Equity stood at -$36.3 million in 2022, then jumped by 108.03% to $2.9 million in 2023, then soared by 95.61% to $5.7 million in 2024, then slumped by 33.29% to $3.8 million in 2025, then soared by 175.71% to $10.5 million in 2026.
- Business Quant data shows AZTR's Common Equity at $10.5 million in Q1 2026, $3.8 million in Q4 2025, and $2.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,769.80 Bn | 1,769.74 Bn | - | -96.14 Mn |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 14.38 Mn |
| 3 | BeOne Medicines | 473.64 Bn | 468.85 Bn | 1.35 Bn | 4.76 Bn |
| 4 | Vertex Pharmaceuticals | 123.74 Bn | 116.49 Bn | 2.59 Bn | 19.36 Bn |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.97 Bn | 3.31 Bn | 31.42 Bn |
| 6 | Belite Bio | 62.10 Bn | 62.10 Bn | - | 795.79 Mn |
| 7 | Argenx Se | 54.68 Bn | 49.49 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.13 Bn | 35.12 Bn | 959.66 Mn | 1.08 Bn |
| 9 | Revolution Medicines | 36.21 Bn | 36.21 Bn | - | 1.50 Bn |
| 10 | Azitra | 2.03 Mn | 2.03 Mn | - | 10.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.48 Mn |
| Dec 31, 2025 | 3.80 Mn |
| Sep 30, 2025 | 2.28 Mn |
| Jun 30, 2025 | 2.20 Mn |
| Mar 31, 2025 | 4.41 Mn |
| Dec 31, 2024 | 5.70 Mn |
| Sep 30, 2024 | 8.06 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Mar 31, 2024 | 4.32 Mn |
| Dec 31, 2023 | 2.91 Mn |
| Sep 30, 2023 | 5.33 Mn |
| Jun 30, 2023 | 7.24 Mn |
| Mar 31, 2023 | -38.68 Mn |
| Dec 31, 2022 | -36.26 Mn |
| Sep 30, 2022 | -32.24 Mn |
| Jun 30, 2022 | -29.87 Mn |